Fremanezumab for the Preventive Treatment of Chronic Migraine [PDF]
New England Journal of Medicine, 2017 Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine.In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of ...
David W Dodick
exaly +5 more sources
Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study [PDF]
The Journal of Headache and PainObjective While erenumab and fremanezumab are effective treatments for migraine prevention, it is unclear whether patients who experience adverse events related to erenumab can tolerate fremanezumab.
Faisal Mohammad Amin +4 more
doaj +3 more sources
Medicus, 2021 Fremanezumab is a humanized, monoclonal IgG2 antibody directed against calcitonin gene-related peptide, developed for specific prophylactic therapy of migraines. The calcitonin gene-related peptide is a vasoactive neuropeptide involved in the nociception and pathogenesis of the migraine.
Luana Lionetto +3 more
core +6 more sources
Frontiers in Neurology, 2023 BackgroundThe effectiveness of fremanezumab in treating migraine has been demonstrated in randomized controlled trials. However, real-world study results are still limited.MethodsWe conducted a single-center, observational study that included patients ...
Yasuo Haruyama +2 more
exaly +3 more sources
Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study [PDF]
The Journal of Headache and Pain, 2021 Background Migraine prevalence is age and sex dependent, predominating in women in early and middle adulthood; however, migraine also represents a substantial burden for men and adults of all ages.
Antoinette MaassenVanDenBrink +7 more
doaj +2 more sources
Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial [PDF]
The Journal of Headache and Pain, 2021 Background The FOCUS study evaluated the efficacy of migraine preventive medications across different countries within the same patient population, particularly for patients with difficult-to-treat migraine. These prespecified subgroup analyses evaluated
Egilius L. H. Spierings +6 more
doaj +2 more sources
Fremanezumab for the treatment of migraine. [PDF]
Pain ManagFremanezumab is a monoclonal antibody inhibiting the CGRP signaling leading to migraine prophylaxis. Its efficacy and potential safety concerns are updated here. All available data on fremanezumab were searched in PubMed with emphasis on the mechanisms of action, efficacy, tolerability, and safety.
Mitsikostas D, Ljubisavljevic S.
europepmc +3 more sources
Three-Year Interim Results from a Post-Marketing Surveillance Study of Patients with Migraine Treated with Fremanezumab in South Korea [PDF]
Drugs - Real World OutcomesBackground There is limited real-world evidence on the safety and effectiveness of fremanezumab in South Korea. Objective We aimed to evaluate the safety and effectiveness of fremanezumab as a preventive migraine treatment in adults with migraine in real-
Dayoung Seo +9 more
doaj +2 more sources
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine [PDF]
Pain and Therapy, 2020 Migraine headache is a common, chronic, debilitating disease with a complex etiology. Current therapy for migraine headache comprises either treatments targeting acute migraine pain or prophylactic therapy aimed at increasing the length of time between ...
Ivan Urits +12 more
doaj +3 more sources
Long-term effectiveness of fremanezumab in episodic and chronic migraine patients in clinical routine – 24-months results from the prospective non-interventional FINESSE study [PDF]
The Journal of Headache and PainBackground The CGRP pathway targeting antibody fremanezumab is indicated for prevention of migraine in adults with ≥4 migraine days/month. To address the limited availability in real-world long-term data, the FINESSE study was initiated to provide real ...
Andreas Straube +6 more
doaj +2 more sources